肝脏免疫微环境的治疗性调控
综述指出炎症是慢性病毒性或免疫介导性肝炎、酒精相关性肝病及NAFLD等进展性肝病的标志,先天与适应性免疫中的细胞因子和细胞应激传感器协调肝脏疾病过程,未消退的炎症和肝损伤导致肝纤维化、肝硬化并可能最终发展为HCC。肝病伴随肠道菌群失调和致病菌扩增助燃肝脏炎症,抗炎策略广泛应用于肝脏以外的人类免疫介导疾病,而肝病免疫调节疗法和细胞疗法的证据才刚出现。肝活检有创监测疗效和DILI风险等临床挑战阻碍了慢性肝病新型免疫调节疗法的开发,新的调控肝脏免疫环境的概念正在研究中。
要点
- 炎症是慢性病毒性/免疫介导性肝炎、酒精相关性肝病及NAFLD等进展性肝病的标志。
- 未消退炎症和肝损伤导致肝纤维化、肝硬化,并可能最终发展为HCC。
- 肝病伴随肠道菌群失调和致病菌扩增,助燃肝脏炎症。
核心结论
- 炎症是进展性肝病的标志,先天与适应性免疫中的细胞因子和细胞应激传感器协调肝脏疾病过程。
- 未消退的炎症和肝损伤导致肝纤维化、肝硬化,并可能最终发展为HCC。
- 肝病伴随肠道菌群失调和致病菌扩增,助燃肝脏炎症。
- 抗炎策略广泛用于肝脏以外的人类免疫介导疾病,而肝病免疫调节疗法和细胞疗法的证据才刚出现。
- 肝活检有创监测疗效和DILI风险等临床挑战阻碍了慢性肝病新型免疫调节疗法的开发。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 炎症是慢性病毒性或免疫介导性肝炎、酒精相关性肝病及NAFLD等进展性肝病的标志。
- 先天与适应性免疫中的细胞因子和细胞应激传感器协调肝脏疾病过程。
- 未消退的炎症和肝损伤导致肝纤维化、肝硬化,并可能最终发展为HCC。
- 肝病伴随肠道菌群失调和致病菌扩增,助燃肝脏炎症。
- 抗炎策略广泛用于肝脏以外的人类免疫介导疾病,而肝病免疫调节疗法和细胞疗法的证据才刚出现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 临床试验中通过肝活检有创监测疗效。
- 多项研究中存在DILI风险。
- 这些方面阻碍了慢性炎症性肝病新型医学疗法的进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation is a hallmark of progressive liver diseases such as chronic viral or immune-mediated hepatitis, alcohol-associated liver disease, and NAFLD. Preclinical and clinical studies have provided robust evidence that cytokines and related cellular stress sensors in innate and adaptive immunity orchestrate hepatic disease processes. Unresolved inflammation and liver injury result in hepatic scarring, fibrosis, and cirrhosis, which may culminate in HCC. Liver diseases are accompanied by gut dysbiosis and a bloom of pathobionts, fueling hepatic inflammation. Anti-inflammatory strategies are extensively used to treat human immune-mediated conditions beyond the liver, while evidence for immunomodulatory therapies and cell therapy-based strategies in liver diseases is only emerging. The development and establishment of novel immunomodulatory therapies for chronic liver diseases has been dampened by several clinical challenges, such as invasive monitoring of therapeutic efficacy with liver biopsy in clinical trials and risk of DILI in several studies. Such aspects prevented advancements of novel medical therapies for chronic inflammatory liver diseases. New concepts modulating the liver immune environment are studied and eagerly awaited to improve the management of chronic liver diseases in the future.
引用
- Tilg H, Adolph TE, Tacke F, et al. Therapeutic modulation of the liver immune microenvironment. Hepatology. 2023. PMID: 37057876. doi:10.1097/HEP.0000000000000386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。